Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
212 hedge funds and large institutions have $752M invested in Sorrento Therapeutics, Inc. in 2021 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 71 increasing their positions, 55 reducing their positions, and 48 closing their positions.
106% more call options, than puts
Call options by funds: $96.7M | Put options by funds: $46.9M
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
29% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 55
17% more capital invested
Capital invested by funds: $641M → $752M (+$110M)
8% less funds holding
Funds holding: 231 → 212 (-19)
38% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 48
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$11.3M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$8.44M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.58M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.55M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
+$3.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$17.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.01M |
| 3 |
California Public Employees Retirement System
Sacramento,
California
|
-$3.9M |
| 4 |
MC
Mayo Clinic
Rochester,
Minnesota
|
-$2.71M |
| 5 |
BlackRock
New York
|
-$2.32M |
SRNE Hedge Fund Activity: Q2 2021 in Review
212 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q2 2021, worth a combined $752M — up 17% from $641M a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of SRNE and 30 opened new positions — a net loss of 18 holders — while 55 trimmed existing stakes and 71 added.
The largest buyer was D.E. Shaw & Co, adding an estimated $11.3M. The largest seller was Cormorant Asset Management, cutting an estimated $17.9M.
- 212 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q2 2021, down from 231 in Q1 2021.
- Funds reported $752M of Sorrento Therapeutics, Inc. stock for Q2 2021, up 17% quarter-over-quarter.
- 30 funds opened new Sorrento Therapeutics, Inc. positions in Q2 2021 and 48 closed out, a net change of -18 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q2 2021 was D.E. Shaw & Co, an estimated $11.3M added.
- The largest Sorrento Therapeutics, Inc. seller in Q2 2021 was Cormorant Asset Management, an estimated $17.9M sold.
Based on aggregated 13F filings for Q2 2021.